Document ID: FDA-2012-N-0218-0025
Agency: fda
Document Type: Rule
Title: Advisory Committee; Antiviral Drugs Advisory Committee; Termination
Posted Date: 2015-03-20T04:00Z

[Federal Register Volume 80, Number 54 (Friday, March 20, 2015)]
[Rules and Regulations]
[Pages 14838-14839]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06425]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 14

[Docket No. FDA-2012-N-0218]

Advisory Committee; Antiviral Drugs Advisory Committee; 
Termination

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
termination of the Antiviral Drugs Advisory Committee. This document 
removes the Antiviral Drugs Advisory Committee from the Agency's list 
of standing advisory committees.

DATES: This rule is effective March 20, 2015.

[[Page 14839]]

FOR FURTHER INFORMATION CONTACT: Michael Ortwerth, Advisory Committee 
Oversight and Management Staff, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 32, Rm. 5129, Silver Spring, MD 20993-0002, 301-
796-8220, FAX: 301-847-8640, or Michael.Ortwerth@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The Antiviral Drugs Advisory Committee was 
established on October 7, 1980 (see 45 FR 79025, November 28, 1980). 
The Committee reviews and evaluates available data concerning the 
safety and effectiveness of marketed and investigational human drug 
products for use in the treatment of acquired immune deficiency 
syndrome, human immunodeficiency virus related illnesses, and other 
viral, fungal and mycobacterial infections. The Committee is no longer 
needed and was terminated on February 15, 2015.
    Under 5 U.S.C. 553(b)(3)(B) and (d) and 21 CFR 10.40(d) and (e), 
the Agency finds good cause to dispense with notice and public comment 
procedures and to proceed to an immediate effective date on this rule. 
Notice and public comment and a delayed effective date are unnecessary 
and are not in the public interest as this final rule merely removes 
the name of the Antiviral Drugs Advisory Committee from the list of 
standing advisory committees in Sec.  14.100 (21 CFR 14.100).
    Therefore, the Agency is amending Sec.  14.100(c) as set forth in 
the regulatory text of this document.

List of Subjects in 21 CFR Part 14

    Administrative practice and procedure, Advisory committees, Color 
additives, Drugs, Radiation protection.

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs, 21 CFR part 
14 is amended as follows:

PART 14--PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE

0
1. The authority citation for 21 CFR part 14 continues to read as 
follows:

    Authority:  5 U.S.C. App. 2; 15 U.S.C. 1451-1461, 21 U.S.C. 41-
50, 141-149, 321-394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42 
U.S.C. 201, 262, 263b, 264; Pub. L. 107-109; Pub. L. 108-155; Pub. 
L. 113-54.

Sec.  14.100  [Amended]

0
2. Section 14.100 is amended by removing paragraph (c)(3) and 
redesignating paragraphs (c)(4) through (18) as paragraphs (c)(3) 
through (17).

    Dated: March 16, 2015.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2015-06425 Filed 3-19-15; 8:45 am]
 BILLING CODE 4164-01-P